Press / Publications

Jan Zimmer´s work in the field of nanodmedicine, contributes to the development of innovative biomaterials for targeted drug delivery and offers promising approaches for future therapeutic applications in gene therapy and cancer research.

The Fraunhofer Institute for Microengineering and Microsystems IMM will par-ticipate as an exhibitor at the international trade fair Hyvolution 2026. The three-day leading event for the hydrogen sector will take place from January 27 to 29, 2026, at Paris Expo Porte de Versailles. The Fraunhofer IMM team will welcome trade visitors at booth N47 in Hall 1, where it will showcase its latest solutions for hydrogen production and power-to-gas processes.

After two years of research and development work, the German-Chilean Power-to-MEDME-R&D project has been successfully completed. The Fraunhofer Institute for Energy Economics and Energy System Technology IEE and its project partners have developed key technological, economic, and systemic foundations for the sustainable production of green hydrogen and its derivatives methanol and dimethyl ether (DME) in Chile. The results show that Chile offers excellent conditions for cost-efficient, cli-mate-neutral production with a high potential for local use and export in an interna-tional comparison.

The team of authors received the GMM Literature Prize 2025 for their publication on a novel system for real-time analysis of nanoparticles during their synthesis. The prize was presented to the lead author, Ebrahim Taiedinejad, at the MikroSystemTechnik Kongress 2025.

With flowDLS, Fraunhofer IMM has developed a system based on dynamic light scattering (DLS) that measures particle sizes in real time. What makes flowDLS special? Read more in our Newsletter "FlowDLS: Real-time precision in nanoparticle analysis".

People being monitored for chronic kidney disease or heart failure often have high levels of potassium in their blood (hyperkalemia) due to impaired renal potassium excretion caused by kidney damage or by medications. But such medications interfere with urinary potassium excretion. This electrolyte imbalance can be life-threatening and thus must be closely monitored. In collaboration with French start-up Ki'tech, researchers at the Fraunhofer Institute for Microengineering and Microsystems IMM want to revolutionize patient monitoring with a minimally invasive solution that measures biomarkers, including potassium, in the subcutaneous interstitial fluid.

We generally feel safe at home. It is where we have designed our sur- roundings according to our preferences and chosen products to the best of our knowledge. But can we truly be sure that these products pose no threat to our health? In the EU-funded project MetrIAQ, Fraunhofer IMM collaborated with several national and international partners to develop novel microcapsules as reference materials for quality assurance in emission testing for the health evaluation of building products.

In his work in the field of reactive intermediates, Lars Gössl focuses on quantity-optimized and demand-driven production of various organozinc halides as well as their conversion into synthetically relevant compounds.

Ammonia has been traditionally known for fertilizer production. In the future, it could also play a key role in the Energy Transition as an efficient source of hydrogen and a climate-friendly substitute for fossil fuels since it can be produced from nitrogen and hydrogen with zero carbon emissions. Furthermore, ammonia offers a wealth of advantages in terms of transportation and storage. The Fraunhofer Institute for Microengineering and Microsystems IMM is working on a space-saving, efficient and, above all, decentralized ammonia cracking technology in numerous research projects.

Fraunhofer IMM, part of the globally renowned Fraunhofer-Gesellschaft, today announced the signing of a Memorandum of Understanding (MoU) with CATUG, Basel, Switzerland. This strategic collaboration will drive joint research and development initiatives, particularly in the fields of nucleic acids and nanoparticle technology. CATUG is a pioneering contract service provider in RNA therapeutics and LNP formulations. The collaboration between Fraunhofer IMM and CATUG will leverage their combined expertise in sustainable technologies, scalable nanoformulation systems, and advanced nanoanalytics. Together, the partnership aims to accelerate innovation in therapeutic solutions, particularly in RNA and lipid nanoparticle (LNP) formulations.

Dr. Johannes Rocker received the a Poster Award at IMRET 2024 in Graz, Austria. His poster, entitled “Electron-mediated Biocatalyzed Synthesis of Chiral Fine Chemicals in Microstructured Flow Reactors,” presents innovative approaches to the electrification of organic syntheses by combining biocatalysis and electrochemistry.

Bright prospects for personalized medicine: Experts from the Fraunhofer Institute for Microengineering and Microsystems IMM harness their know-how in microfluidics and single-cell technologies to print organ structures. They will be presenting their developments at the joint Fraunhofer booth (Hall 3, Booth E74) at the MEDICA 2024 trade show from November 11 to 14.

Parker Hannifin and the Fraunhofer Institute for Microengineering and Microsystems (IMM) today announced the renewal of their partnership to further develop air adsorption technology for fuel cell humidification applications. Gregory Brickett, General Manager, Engine Mobile Filtration Europe (EMFE) Division, said: “This collaboration builds on the successful partnership which started in October 2022, and which led to significant advancements in fuel cell technology, including the development of a specialized test rig.”

We congratulate Eva Deitmann on the successful defense of her Doctoral thesis. Deitmann's thesis deals with the continuous, scalable formation of Grignard reagents.

Transport and trade on the ocean blue must be made much greener. This is the goal of the new €17 million European GAMMA project, where companies and researchers from Europe will develop and convert a bulk carrier to sail on climate-neutral fuels and green power.

mRNA-based vaccines and gene/cell therapeutics open up new possibilities for medical practitioners in the fight against cancer and infectious or hereditary diseases. However, manufacturing these innovative pharmaceuticals is an expensive and time-consuming process. The Fraunhofer RNAuto lighthouse project is aiming to use automated production technologies to facilitate cost-effective, high-volume production of mRNA-based drugs and medicines for personalized therapies which can then be made available at an affordable price. From November 13 to 16, researchers from the Fraunhofer-Gesellschaft will, for the first time, present a screening system demonstrator for the automated encapsulation of mRNA in nanotransporters at COMPAMED in Düsseldorf (Hall 8a, Booth G10).

Electrochemical processes like water electrolysis will become increasingly important in the future in light of climate change and the resultant need for an energy and raw materials transition. The Fraunhofer Institute for Microengineering and Microsystems IMM is collaborating with hte GmbH to develop modular electrochemical cells. These flow cells are used in screening tasks, thereby helping optimize electrochemical production processes, such as water electrolysis.

In his thesis in the field of electrochemistry, Nils Baumgarten describes an electrochemical microreactor for carrying out electrochemical syntheses in continuous operation and studies the influence of operating conditions on selectivity and energy efficiency.